Phase 2 N=3 Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia
Post Bariatric Hypoglycemia
Primary: Nadir Glucose — 41; 43; 39; 42 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=112 Sequential Multiple Assignment Treatment for Bipolar Disorder
Bipolar I Disorder · Bipolar II Disorder
Primary: Bipolar Inventory of Symptoms Scale (BISS) — -0.31; -0.41; 0.15; -0.38 calculated mean scale score
N/A N=150 Negative Pressure Wound Therapy as a Drug Delivery System
Diabetic Foot Ulcers
Primary: Number of Participants Who Achieved Complete Healing or Coverage of the Study Wound — 44; 45 Participants — p=0.87
N/A N=31 Left Ventricular Synchronous Versus Sequential MultiSpot Pacing for Cardiac Resynchronization Therapy (CRT)
Heart Failure
Primary: Percentage Change in Positive Left Ventricular dP/dt Max (mmHG/Sec) — 10.59; 12.20; 11.51; 15.64 % change LV dP/dt max
Phase 3 N=352 Comparison of Bowel Cleansing Efficacy Between Same-day Dose Versus Split Dose
Unrecognized Condition
Primary: Boston Bowel Preparation Scale — 169; 163 Number of successful cleansing
N/A N=23 Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers
Foot Ulcer, Diabetic
Primary: Tissue Oxygenation as Measured by Hyperspectral Imaging — 63.58; 61.91; 76.33; 77.55 percent concentration of oxyhemoglobin
Phase 3 N=367 Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
Dermatitis, Atopic
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 — 11.4; 32.8; 29.5 Percentage of Participants — p== 0.0004
Phase 3 N=473 Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures
Epilepsy · Partial-onset Seizures
Primary: Number of Participants With at Least One Adverse Event Reported Spontaneously by the Subject or Observed by the Investigator From Baseline Until the End of Study Visit…
N/A N=164 Soiled Airway Tracheal Intubation and the Effectiveness of Decontamination by Paramedics
Airway Management · Intubation, Intratracheal · Laryngoscopy
Primary: Difference in First-pass Intubation Success Rates Before and After SALAD Training — 44; 74 Participants
Phase 1 N=11 Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events — 75.0; 33.3 percentage of participants
Phase 4 N=16 Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)
Asthma
Primary: The Mean Area Under the Curve (AUC) of Forced Expiratory Volume in One Second (FEV-1) Over 12 Hours, Measured (BL), 5, 10, 15, 60, 120, 240, 480, 720 Minutes. The Unit…
Phase 2 N=18 Pregabalin as Treatment for Alcohol Use Disorder
Alcohol Use Disorder
Primary: Maximum Dose of Pregabalin: — 571.4 milligrams
Phase 2 N=56 Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy
Prostate Cancer · Erectile Dysfunction
Primary: Erectile Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire Erectile Function Domain — 14; 19 score on a scale
N/A N=40 Self Abrading Rapidly Applied Electrode Validation
ELECTROENCEPHALOGRAPHIC VARIANT PATTERN 1 (Disorder)
Primary: Signal Quality Comparison Between SARA Electrode and Gold Cup Electrode — 30; 45 seconds
Phase 3 N=560 Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)
Type 2 Diabetes
Primary: Change in HbA1c From Baseline to 24 Weeks — -0.6; -0.66 percent